Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Down 8.5% – Should You Sell?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares traded down 8.5% during trading on Wednesday . The stock traded as low as $1.5710 and last traded at $1.5650. 677,704 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 2,592,519 shares. The stock had previously closed at $1.71.

Analysts Set New Price Targets

LXRX has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.23.

Lexicon Pharmaceuticals Trading Down 19.4%

The stock has a market cap of $421.54 million, a PE ratio of -6.11 and a beta of 0.71. The company’s fifty day moving average is $1.31 and its 200-day moving average is $1.28. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.64 and a quick ratio of 5.63.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. The business had revenue of $14.18 million for the quarter, compared to analyst estimates of $5.81 million. Lexicon Pharmaceuticals had a negative return on equity of 52.90% and a negative net margin of 96.77%. On average, analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in LXRX. R Squared Ltd raised its position in shares of Lexicon Pharmaceuticals by 45.3% during the 4th quarter. R Squared Ltd now owns 46,579 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 14,530 shares during the last quarter. UBS Group AG grew its holdings in shares of Lexicon Pharmaceuticals by 752.1% in the fourth quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company’s stock valued at $3,458,000 after purchasing an additional 2,654,315 shares during the period. Hennion & Walsh Asset Management Inc. grew its stake in shares of Lexicon Pharmaceuticals by 15.7% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 901,222 shares of the biopharmaceutical company’s stock valued at $1,036,000 after buying an additional 122,010 shares during the period. Vermillion & White Wealth Management Group LLC grew its position in Lexicon Pharmaceuticals by 400.0% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 26,000 shares during the period. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at $3,240,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.